Our anti-HIV jab will be rolled out in six weeks. But funding cuts hollowed out the system needed to deliver it
The uptake of the once-every-six-month HIV prevention jab lenacapavir (LEN) in South Africa will be heavily affected by the Trump administration’s funding cuts to the country, a new report has found. Researchers conducted in-depth interviews with doctors, nurses, peer counsellors, transgender and young people, sex workers, gay and bisexual men and government health workers with personal experience of the funding cuts in Cape Town and Johannesburg
